The effectiveness of the Russian anti-COVID-19 vaccine Sputnik V looks very encouraging, and changing the drug in case of a virus mutation will not carry difficulties to manufacturers, said Nobel Prize laureate in physiology and medicine, Australian virologist Peter Doherty.
“Efficiency – more than 90% – looks great, and besides, Russia has a long history of developing good vaccines. The strategy of using two adenovirus vectors makes sense, and as I understand it, is used in the “Sputnik.” Of course, if the virus changes significantly as a result of the mutation, it seems that now it is in the process of transformation, it will have to “correct” the drug a little, but this will not be difficult”, TASS quoted Doherty.
He also noted that the strategy of using two adenoviral vectors was also used in the creation of vaccines by the pharmacological companies Janssen and AstraZeneca.
Peter Charles Doherty is an Australian scientist, virologist and immunologist, laureate of the 1996 Nobel Prize in Physiology or Medicine for discoveries in the human immune system, in particular its ability to detect cells affected by the virus.